Skip to Content

Join the 'VESIcare' group to help and get support from people like you.

VESIcare News

FDA Approves Supplemental New Drug Application for Myrbetriq (mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder Symptoms

Posted 5 Jun 2018 by Drugs.com

TOKYO, May 7, 2018 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of...

Ask a Question

Further Information

Related Condition Support Groups

Overactive Bladder, Urinary Incontinence

VESIcare Patient Information at Drugs.com